BioSpace News Archive

Have you ever been too intimidated to speak up or challenge a tenured professional at work? Many people who are in the early stages of their career might feel uncomfortable around others who have 10, 20, or 30+ years of experience.

The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)

Prof. Dr. Helga Rübsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, were awarded the German Future Prize 2018 (German President’s Award for Innovation in Science and Technology) presented by the German Federal President, Frank-Walter Steinmeier

Probiodrug AG today announces its third quarter business update for the period ending September 30, 2018.

The conference shed light on varied areas pertaining to reproductive medicine as it explored potential treatment and solutions for Assisted Reproductive Technologies

Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.

The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.